Agios Pharmaceuticals reported $-116.87M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.72B 69M Jun/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amgen USD 4.43B 2.17B Sep/2025
Arrowhead Research USD 57.82M 223.36M Sep/2025
Astellas Pharma JPY 104.41B 11.87B Sep/2025
AstraZeneca USD -1.5B 5.01B Sep/2025
Bayer EUR -399M 363M Sep/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Bristol-Myers Squibb USD 4.04B 1.78B Sep/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Exelixis USD 256.36M 42.78M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
GlaxoSmithKline GBP 2.79B 716M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Merck USD 7.56B 1.19B Sep/2025
Moderna USD -260M 557M Sep/2025
Novartis USD -9.19B 13.87B Jun/2025
Novartis USD 4.48B 343M Sep/2025
Pfizer USD 4.57B 1.97B Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 2.1B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025